Advil pm: adverse event reports filed with FDA

4,978

reports as suspect product

0% of all reports · about 249 a year

134

reports, 12 months to June 2026

199 in the 12 months before

11.1%

marked serious by the reporter

71.8% across the class

0.2%

record death among outcomes, as reported

8 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Advil pm reports recording the termmedian drug in nonsteroidal anti-inflammatory drug

1. Drug ineffectivethe medicine did not work as expected23.9%1,188
2. Product use in unapproved indicationused for a purpose not on the label19.4%964
3. Drug effective for unapproved indication17.3%862
4. Somnolencedrowsiness11.7%581
5. Insomniadifficulty sleeping4.3%215
6. Feeling abnormalfeeling odd or not right4%198
7. Dizzinesslight-headedness or unsteadiness3%148
8. Intentional product misusedeliberate use not as intended2.8%138
9. Fatiguetiredness2.7%133
10. Overdosea dose above the recommended amount2.2%108
11. Incorrect dose administeredthe wrong dose was given2.1%107
12. Drug effect incomplete1.9%96
13. Malaisegeneral feeling of being unwell1.8%91
14. Headachehead pain1.8%90
15. Therapeutic product effect incomplete1.7%86
16. Dysphagiadifficulty swallowing1.6%80
17. Restlessnessrestlessness1.6%80
18. Drug effect decreasedthe medicine had less effect1.6%78
19. Therapeutic response unexpected1.3%65
20. Nauseafeeling sick1.3%64
21. Abdominal discomfortstomach discomfort1.3%63
22. Condition aggravatedthe condition being treated got worse1.2%62
23. Product use issuea problem in how the product was used1.2%61
24. Restless legs syndrome1.2%59
25. Drug ineffective for unapproved indication1.1%55
26. Abdominal pain upperupper stomach pain1.1%54
27. Intentional product use issuedeliberate use not as intended1%52
28. Nightmarenightmares1%49
29. Feeling jittery0.9%47
30. Painpain, site not specified0.9%47

Top 30 of 330 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 47 drugs in the nonsteroidal anti-inflammatory drug class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 548,672 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 99.8% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 4,978 reports.

Drugs most often listed in the same reports

Other products listed in reports where Advil pm is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the nonsteroidal anti-inflammatory drug class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Advil pm as a suspect or interacting product; reports listing it only as a concomitant medication (557) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.